ibrutinib + acalabrutinib + zanubrutinib

This is a hypothetical combination of three covalent Bruton's tyrosine kinase (BTK) inhibitors: ibrutinib, acalabrutinib, and zanubrutinib. All three are small molecule drugs that irreversibly inhibit BTK, a key enzyme in the B-cell receptor signaling pathway essential for the survival and proliferation of malignant B cells. Ibrutinib is the first-in-class BTK inhibitor with broad clinical use but notable off-target effects. Acalabrutinib and zanubrutinib are second-generation agents designed to be more selective for BTK, resulting in improved safety profiles compared to ibrutinib[2][3][8]. Each drug is approved as monotherapy or in combination with other agents for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, and other B-cell malignancies[2][6][8]. There is no evidence or clinical precedent for combining all three BTK inhibitors together; such a regimen would likely be redundant due to their shared mechanism of action.

Brand names

Imbruvica (ibrutinib)Calquence (acalabrutinib)Brukinsa (zanubrutinib)